Form 4: Kiniksa COO Sells Shares After Option Exercise

Kiniksa Pharmaceuticals COO Eben Tessari exercised options and immediately sold 200 Class A Ordinary Shares for a profit, as part of a pre-arranged 10b5-1 plan.

Summary

• Eben Tessari, Chief Operating Officer of Kiniksa Pharmaceuticals International, plc, reported a transaction involving Class A Ordinary Shares.
• On November 26, 2025, Mr. Tessari acquired 200 Class A Ordinary Shares by exercising stock options at a price of $22.89 per share.
• Immediately following the acquisition, Mr. Tessari disposed of 200 Class A Ordinary Shares at a price of $42.89 per share.
• Both transactions were executed pursuant to a Rule 10b5-1 plan, which was established on April 29, 2024.
• After these transactions, Mr. Tessari's direct beneficial ownership of Class A Ordinary Shares stands at 22,714.
• The exercised option was fully vested and exercisable, with an expiration date of March 15, 2031.
• Mr. Tessari continues to beneficially own 46,938 derivative securities (share options) after the reported transaction.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, pre-planned insider transaction (exercise and sell) under a 10b5-1 plan. It does not reflect new material information about the company's operational or financial performance.

Positives

• The Chief Operating Officer realized a profit of $20.00 per share ($42.89 sale price $22.89 exercise price) on 200 shares, totaling $4,000, through the exercise of options and subsequent sale.
• The transaction was conducted under a pre-arranged 10b5-1 plan, indicating a scheduled, non-discretionary sale not based on new material non-public information.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by the market, though the small volume and 10b5-1 plan mitigate this concern.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction. It solely reports an insider transaction.

Management Comments

• The transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.
• The option is fully vested and exercisable.

Industry Context

This filing is a routine insider transaction report and does not provide information directly related to broader industry trends or competitive landscape. It reflects an individual executive's pre-planned stock activity.

Stakeholder Impact

• Shareholders: The transaction is a routine insider sale under a 10b5-1 plan, which typically has minimal impact on shareholder sentiment or the company's valuation. The volume of shares sold is relatively small.

Key Dates

Recommendation

This Form 4 reports a routine, pre-planned insider transaction (exercise and sell) by the COO. It does not provide new fundamental information about Kiniksa Pharmaceuticals International, plc that would warrant a change in investment recommendation. The transaction was executed under a 10b5-1 plan, indicating it was scheduled in advance and not based on new material non-public information. Therefore, a 'hold' recommendation remains appropriate as the filing does not alter the company's underlying investment thesis.

Keywords

Kiniksa Pharmaceuticals, KNSA, Eben Tessari, COO, Insider Transaction, Form 4, Stock Options, Share Sale, 10b5-1 Plan